| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Novavax Inc (NVAX) has 8 insiders with recent SEC Form 4 filings, including 8 buys and 2 sells. NVAX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 264.1K | $2.38M | - | |
| CFO | 145.1K | $1.31M | - | |
| VP | 112.7K | $1.01M | - | |
| VP | 34.9K | $313.9K | - | |
| Dir | 28.5K | $256.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 9, 2017 | Glenn Gregory M88 | President, R&D | Buy | 10,000 | $1.13 | $11,300.00 | +225.9% | |
| Nov 9, 2017 | Erck Stanley C86 | President And CEO | Buy | 100,000 | $1.13 | $113,050.00 | +78.0% | |
| Aug 31, 2017 | Young James F82 | Director | Sell | 175,000 | $1.06 | $184,870.00 | -100% | |
| Jul 31, 2017 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 2,057 | $0.89 | $1,830.73 | +5.6% | |
| May 12, 2017 | McManus Michael A Jr81 | Director | Buy | 20,000 | $0.97 | $19,396.00 | +7.8% | |
| May 11, 2017 | Phillips Barclay A | SVP, Chief Financial Officer | Buy | 25,000 | $0.84 | $20,950.00 | +215.3% | |
| May 11, 2017 | Erck Stanley C86 | President And CEO | Buy | 50,000 | $0.84 | $41,980.00 | +63.9% | |
| May 11, 2017 | Douglas Richard | Director | Buy | 200,000 | $0.93 | $185,780.00 | +57.1% | |
| May 11, 2017 | McManus Michael A Jr81 | Director | Buy | 10,000 | $0.84 | $8,400.00 | +4.0% | |
| Mar 14, 2017 | Young James F82 | Director | Sell | 100,000 | $1.39 | $138,980.00 | -36.4% |